Evaluating [225Ac]Ac-FAPI-46 for the treatment of soft-tissue sarcoma in mice
European Journal of Nuclear Medicine and Molecular Imaging · 2024-11 · 51 (13) · 4026-4037
DOI: 10.1007/s00259-024-06809-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 15.07.2024. Verfasst von Marco F Taddio und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. mtaddio@protonmail.com. Hauptthemen laut MEDLINE: Sarcoma, Endopeptidases. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Prostate Cancer Foundation, Jonsson Comprehensive Cancer Center, NCI NIH HHS.
Abstract (Originalsprache)
Purpose Fibroblast Activation Protein (FAP) is an emerging theranostic target that is highly expressed on cancer-associated fibroblasts and on certain tumor cells including sarcoma. We investigated the anti-tumor efficacy of [ 225 Ac]Ac-FAPI-46 as monotherapy or in combination with immune checkpoint blockade (ICB) in immunocompetent murine models of sarcoma sensitive or resistant to ICB. Methods [ 68 Ga]Ga- and [ 225 Ac]Ac-FAPI-46 were tested in subcutaneous FAP+ FSA fibrosarcoma bearing C3H/Sed/Kam mice. The efficacy of up to three cycles of 60 kBq [ 225 Ac]Ac-FAPI-46 was evaluated as monotherapy and in combination with an anti-PD-1 antibody. Efficacy of [ 225 Ac]Ac-FAPI-46 and/or ICB was further compared in FAP-overexpressing FSA (FSA-F) tumors that were sensitive to ICB or rendered ICB-resistant by tumor-induction in the presence of Abatacept. Results [ 225 Ac]Ac-FAPI-46 was well tolerated up to 3 × 60 kBq but had minimal effect on FSA tumor growth. The combination of three cycles [ 225 Ac]Ac-FAPI-46 and ICB resulted in growth delay in 55% of mice (6/11) and partial tumor regression in 18% (2/11) of mice. In FSA-F tumors with FAP overexpression, both [ 225 Ac]Ac-FAPI-46 and ICB were effective without additional benefits from the combination. In locally immunosuppressed and ICB resistant FAP-F tumors, however, [ 225 Ac]Ac-FAPI-46 restored responsiveness to ICB, resulting in significant tumor regression and tumor-free survival of 56% of mice in the combination group up to 60 days post treatment. Conclusion [ 225 Ac]Ac-FAPI-46 efficacy is correlated with tumoral FAP expression levels and can restore responsiveness to PD-1 ICB. These data illustrate that careful patient selection based on target expression and rationally designed combination therapies are critically important to maximize the therapeutic impact of FAP-targeting radioligands.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. mtaddio@protonmail.com.
- Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
- Department of Radiation Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
- Department of Nuclear Medicine, University of Duisburg-Essen, and German Cancer Consortium (DKTK)-University Hospital Essen, Essen, Germany.
ORCID-Profile: Marco F Taddio
Förderung
- Prostate Cancer Foundation
- Jonsson Comprehensive Cancer Center
- NCI NIH HHS
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
Zitieren
APA
Taddio, M. F., Doshi, S., Masri, M., Jeanjean, P., Hikmat, F., Gerlach, A., Nyiranshuti, L., Rosser, E. W., Schaue, D., Besserer-Offroy, E., Carlucci, G., Radu, C. G., Czernin, J., Lückerath, K., & Mona, C. E. (2024). Evaluating [225Ac]Ac-FAPI-46 for the treatment of soft-tissue sarcoma in mice. European Journal of Nuclear Medicine and Molecular Imaging, 51(13), 4026-4037. https://doi.org/10.1007/s00259-024-06809-4
Vancouver
Taddio MF, Doshi S, Masri M, Jeanjean P, Hikmat F, Gerlach A, et al. Evaluating [225Ac]Ac-FAPI-46 for the treatment of soft-tissue sarcoma in mice. European Journal of Nuclear Medicine and Molecular Imaging. 2024;51(13):4026-4037. doi:10.1007/s00259-024-06809-4
BibTeX
@article{Taddio2024,
author = {Taddio, Marco F and Doshi, Suraj and Masri, Marwan and Jeanjean, Pauline and Hikmat, Firas and Gerlach, Alana and Nyiranshuti, Lea and Rosser, Ethan W and Schaue, Dorthe and Besserer-Offroy, Elie and Carlucci, Giuseppe and Radu, Caius G and Czernin, Johannes and Lückerath, Katharina and Mona, Christine E},
title = {Evaluating [225Ac]Ac-FAPI-46 for the treatment of soft-tissue sarcoma in mice},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2024},
volume = {51},
number = {13},
pages = {4026--4037},
doi = {10.1007/s00259-024-06809-4}
}
EUVIMED